c-Met/HGFR
c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
All Product Categories
-
c-Met/HGFR Inhibitors
(239)
View all products
-
c-Met/HGFR Agonist
(1)
View all products
-
c-Met/HGFR Activators
(4)
View all products
-
c-Met/HGFR Modulators
(3)
View all products
-
c-Met/HGFR Degraders
(11)
View all products
-
c-Met/HGFR Ligands
(5)
View all products
-
c-Met/HGFR Proteins
(48)
View all products
-
c-Met/HGFR Related Products (285)
Related Products (285)
-
Recombinant Proteins (48)
-
Antibodies (7)
-
MET Y1235D Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70758Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions.
-
c-Met-IN-19
0 ImagesCat. No.: HY-156098CAS No.: 3098360-50-7c-Met-IN-19 (Compound 21j) is a c-Met inhibitor (IC50: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC50s of 0.25, 0.36, 0.98, 0.76 μM.
-
c-Met-IN-31
0 ImagesCat. No.: HY-181776c-Met-IN-31 is a c-Met inhibitor with an IC50 value of 0.021 μM. c-Met-IN-31 also inhibits VEGFR-2 and EGFR activities, with IC50 values of 0.32 μM and 9.3 μM, respectively. c-Met-IN-31 inhibits cancer cell proliferation. c-Met-IN-31 suppresses neovascularization in the chick chorioallantoic membrane (CAM) assay, exhibiting in vivo anti-angiogenic activity. c-Met-IN-31 can be used in research related to breast cancer and lung cancer.
-
CRI9
0 ImagesCat. No.: HY-168609CRI9 inhibits the c-MET/PI3K/Akt/mTOR pathway, suppressing the growth of liver cancer cells. CRI9 shows strong cytotoxicity against HCC cells, inducing apoptosis.
-
PROTAC c-Met degrader-6
0 ImagesCat. No.: HY-175321PROTAC c-Met degrader-6 is an orally active c-Met PROTAC degrader with DC50 values of 0.52 nM (EBC-1) and 0.45 nM (Hs746T), respectively. PROTAC c-Met degrader-6 induces potent targeted degradation of c-Met via the ubiquitin-proteasome system by bridging the target protein c-Met and the Cullin-CRBN E3 ubiquitin ligase to form a ternary complex, thereby inducing tumor cell cycle arrest and apoptosis. PROTAC c-Met degrader-6 can be used in the research of various MET-driven cancers (such as gastric cancer, liver cancer, non-small cell lung cancer, etc.).
-
VERT-002
0 ImagesCat. No.: HY-P992481VERT-002 is a MET degrader and monoclonal antibody. VERT-002 induces nearly complete and profound degradation of the MET protein by enhancing the intrinsic shedding of the MET extracellular domain (ECD). VERT-002 demonstrates significant anti-tumor activity. VERT-002 can be used in non-small cell lung cancer research..
-
CM-118
0 ImagesCat. No.: HY-165284CAS No.: 1370652-56-4CM-118 is a potent and selective c-Met and ALK inhibitor. CM-118 inhibits the HGF-induced c-Met phosphorylation. CM-118 inhibits phosphorylation of ALK, EML4-ALKv1, ALK F1174L, and EMl4-ALKv1 L1196M, with respective IC50 values 0.92, 1.25, 1.9, and 3.5 μM. CM-118 exhibits anticancer activity against cancers dependent on the c-Met or ALK oncogenic pathways.
-
Multi-kinase-IN-1
0 ImagesCat. No.: HY-146014CAS No.: 2470807-67-9Multi-kinase-IN-1 (Compound 11k) is a potent kinase inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell apoptosis, and can be studied for colorectal cancer.
-
DOTA-SMIC-1014
0 ImagesCat. No.: HY-P11864DOTA-SMIC-1014 is a DOTA chelator-conjugated precursor of the c-Met-targeting peptide SMIC-1014 (HY-P11863). DOTA-SMIC-1014 binds to the extracellular domain of c-Met (Kd = 42.83 nM). After radiolabeling to [68Ga]Ga-SMIC-1014, DOTA-SMIC-1014 acts as a positron emission tomography (PET) probe that achieves specific tumor uptake in xenografts and functions as a diagnostic probe targeting c-Met. SMIC-1014 can be used in research related to colon cancer, hepatocellular carcinoma, and prostate cancer.
-
c-Met-IN-21
0 ImagesCat. No.: HY-157302CAS No.: 3025958-01-1c-Met-IN-21 (compound 54) is a c-met inhibitor with an IC50 value of 0.45? nM, and shows anti-tumor efficacy in vivo.
-
c-Met-IN-10
0 ImagesCat. No.: HY-146274CAS No.: 2415291-03-9c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC50 value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC50s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer.
-
(3S,4S)-Tivantinib
0 ImagesSynonyms: (3S,4S)-ARQ 197; ARQ 198(3S,4S)-Tivantinib is a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET. (3S,4S)-Tivantinib has two novel targets, GSK3α and GSK3β, which play an important role in the cellular mechanism of non-small cell lung cancer (NSCLC).
-
Foretinib phosphate
0 ImagesCat. No.: HY-10338ACAS No.: 1226999-07-0Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB.
-
GNE-203
0 ImagesCat. No.: HY-182458CAS No.: 949560-05-8GNE-203 is a heterobicyclic pyrazole compound and receptor tyrosine kinase inhibitor targeting c-Met.GNE-203 can be used for the research of cancer.
-
SMU-B
0 ImagesCat. No.: HY-120387CAS No.: 1253286-90-6
-
EMI-137
0 ImagesCat. No.: HY-D3352CAS No.: 1081979-12-5Synonyms: AGSCYCSGPPRFECWCYETEGT-Cy5EMI-137 (AGSCYCSGPPRFECWCYETEGT-Cy5) is a fluorescent imaging agent targeting the c-Met receptor. EMI-137 specifically binds to the extracellular domain of the c-Met receptor and is used for fluorescent visualization of c-Met-expressing cells and tissues. EMI-137 can be applied to research related to colorectal cancer.
-
Norleual
0 ImagesCat. No.: HY-P1415CAS No.: 334994-34-2Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities.
-
Antimetastatic agent-1
0 ImagesCat. No.: HY-164100CAS No.: 713505-06-7
-
c-Met-IN-12
0 ImagesCat. No.: HY-147695CAS No.: 2426675-70-7c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy.
